Biosearch Technologies

Last updated
LGC Biosearch Technologies
FormerlyBiosearch Technologies, Inc.
Company typePrivate
IndustryBiotechnology
Founded1993
Headquarters Hoddesdon, United Kingdom
Number of locations
11
Key people
Tim Robinson
CEO
Number of employees
778 (2023)  OOjs UI icon edit-ltr-progressive.svg
Parent LGC Ltd   OOjs UI icon edit-ltr-progressive.svg
Website Biosearchtech.com

LGC Biosearch Technologies is a biotechnology company headquartered in Hoddesdon, UK. It is a subsidiary of LGC Ltd specializing in nucleic acid production, PCR systems, and other molecular biology lab kits and services. [1] [2]

Contents

Part of the Genomics Division of LGC, Biosearch Technologies has a network of nine manufacturing facilities and three service labs in the US and Europe, and serves customers across a number of markets including pharmaceuticals, agricultural biotechnology, diagnostics, food safety, environment, government and academia.

History

Biosearch Technologies was founded in 1993, inheriting expertise from founder Dr. Ronald Cook's previous venture, Biosearch Inc, which produced DNA synthesis instruments.

In 2013, Biosearch Technologies acquired the oligonucleotide manufacturing arm of DNA Technology and the entirety of VitraBio, a maker of porous glass. [3]

In 2015, Biosearch Technologies was acquired by LGC. [4] In 2016, Douglas Scientific was also acquired by LGC, and merged operations with Biosearch Technologies. [5]

Recognition in PCR research

When Kary Mullis received the Nobel Prize in 1993 and gave his Nobel Lecture concerning his invention of the polymerase chain reaction (PCR) method, he acknowledged Biosearch Inc and Dr. Cook's role in providing him one of the first SAM I DNA synthesizers which was used to support Kary Mullis' PCR research. [6]

Products

Biosearch Technologies licenses products meant for lab work and biotechnology manufacturing, including dyes and primers, as well as Stellaris FISH probes. [7] [8] In the past, they have developed detection panels for both H1N1 and Avian Influenza A. In addition, they offer a web-based software called RealTimeDesign to help scientists craft custom oligonucleotides. [9]

Related Research Articles

<span class="mw-page-title-main">Kary Mullis</span> American biochemist (1944–2019)

Kary Banks Mullis was an American biochemist. In recognition of his role in the invention of the polymerase chain reaction (PCR) technique, he shared the 1993 Nobel Prize in Chemistry with Michael Smith and was awarded the Japan Prize in the same year. PCR became a central technique in biochemistry and molecular biology, described by The New York Times as "highly original and significant, virtually dividing biology into the two epochs of before PCR and after PCR."

<span class="mw-page-title-main">Polymerase chain reaction</span> Laboratory technique to multiply a DNA sample for study

The polymerase chain reaction (PCR) is a method widely used to make millions to billions of copies of a specific DNA sample rapidly, allowing scientists to amplify a very small sample of DNA sufficiently to enable detailed study. PCR was invented in 1983 by American biochemist Kary Mullis at Cetus Corporation. Mullis and biochemist Michael Smith, who had developed other essential ways of manipulating DNA, were jointly awarded the Nobel Prize in Chemistry in 1993.

<span class="mw-page-title-main">Michael Smith (chemist)</span> British-born Canadian biochemist, businessman and Nobel Prize laureate (1932–2000)

Michael Smith was a British-born Canadian biochemist and businessman. He shared the 1993 Nobel Prize in Chemistry with Kary Mullis for his work in developing site-directed mutagenesis. Following a PhD in 1956 from the University of Manchester, he undertook postdoctoral research with Har Gobind Khorana at the British Columbia Research Council in Vancouver, British Columbia, Canada. Subsequently, Smith worked at the Fisheries Research Board of Canada Laboratory in Vancouver before being appointed a professor of biochemistry in the UBC Faculty of Medicine in 1966. Smith's career included roles as the founding director of the UBC Biotechnology Laboratory and the founding scientific leader of the Protein Engineering Network of Centres of Excellence (PENCE). In 1996 he was named Peter Wall Distinguished Professor of Biotechnology. Subsequently, he became the founding director of the Genome Sequencing Centre at the BC Cancer Research Centre.

<i>Thermus aquaticus</i> Species of bacterium

Thermus aquaticus is a species of bacteria that can tolerate high temperatures, one of several thermophilic bacteria that belong to the Deinococcota phylum. It is the source of the heat-resistant enzyme Taq DNA polymerase, one of the most important enzymes in molecular biology because of its use in the polymerase chain reaction (PCR) DNA amplification technique.

Site-directed mutagenesis is a molecular biology method that is used to make specific and intentional mutating changes to the DNA sequence of a gene and any gene products. Also called site-specific mutagenesis or oligonucleotide-directed mutagenesis, it is used for investigating the structure and biological activity of DNA, RNA, and protein molecules, and for protein engineering.

<i>Taq</i> polymerase Thermostable form of DNA polymerase I used in polymerase chain reaction

Taq polymerase is a thermostable DNA polymerase I named after the thermophilic eubacterial microorganism Thermus aquaticus, from which it was originally isolated by Chien et al. in 1976. Its name is often abbreviated to Taq or Taq pol. It is frequently used in the polymerase chain reaction (PCR), a method for greatly amplifying the quantity of short segments of DNA.

Sigma-Aldrich is an American chemical, life science, and biotechnology company owned by the multinational chemical conglomerate Merck Group

<span class="mw-page-title-main">Molecular beacon</span>

Molecular beacons, or molecular beacon probes, are oligonucleotide hybridization probes that can report the presence of specific nucleic acids in homogenous solutions. Molecular beacons are hairpin-shaped molecules with an internally quenched fluorophore whose fluorescence is restored when they bind to a target nucleic acid sequence. This is a novel non-radioactive method for detecting specific sequences of nucleic acids. They are useful in situations where it is either not possible or desirable to isolate the probe-target hybrids from an excess of the hybridization probes.

<span class="mw-page-title-main">Cetus Corporation</span> Pioneering biotech company in California, US

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California, in 1971, but conducted most of its operations in nearby Emeryville. Before merging with Chiron Corporation in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

TaqMan probes are hydrolysis probes that are designed to increase the specificity of quantitative PCR. The method was first reported in 1991 by researcher Kary Mullis at Cetus Corporation, and the technology was subsequently developed by Hoffmann-La Roche for diagnostic assays and by Applied Biosystems for research applications.

SNP genotyping is the measurement of genetic variations of single nucleotide polymorphisms (SNPs) between members of a species. It is a form of genotyping, which is the measurement of more general genetic variation. SNPs are one of the most common types of genetic variation. An SNP is a single base pair mutation at a specific locus, usually consisting of two alleles. SNPs are found to be involved in the etiology of many human diseases and are becoming of particular interest in pharmacogenetics. Because SNPs are conserved during evolution, they have been proposed as markers for use in quantitative trait loci (QTL) analysis and in association studies in place of microsatellites. The use of SNPs is being extended in the HapMap project, which aims to provide the minimal set of SNPs needed to genotype the human genome. SNPs can also provide a genetic fingerprint for use in identity testing. The increase of interest in SNPs has been reflected by the furious development of a diverse range of SNP genotyping methods.

An allele-specific oligonucleotide (ASO) is a short piece of synthetic DNA complementary to the sequence of a variable target DNA. It acts as a probe for the presence of the target in a Southern blot assay or, more commonly, in the simpler dot blot assay. It is a common tool used in genetic testing, forensics, and molecular biology research.

Biomolecular engineering is the application of engineering principles and practices to the purposeful manipulation of molecules of biological origin. Biomolecular engineers integrate knowledge of biological processes with the core knowledge of chemical engineering in order to focus on molecular level solutions to issues and problems in the life sciences related to the environment, agriculture, energy, industry, food production, biotechnology and medicine.

The following outline is provided as an overview of and topical guide to genetics:

<span class="mw-page-title-main">Oligomer restriction</span>

Oligomer Restriction is a procedure to detect an altered DNA sequence in a genome. A labeled oligonucleotide probe is hybridized to a target DNA, and then treated with a restriction enzyme. If the probe exactly matches the target, the restriction enzyme will cleave the probe, changing its size. If, however, the target DNA does not exactly match the probe, the restriction enzyme will have no effect on the length of the probe. The OR technique, now rarely performed, was closely associated with the development of the popular polymerase chain reaction (PCR) method.

<span class="mw-page-title-main">History of polymerase chain reaction</span>

The history of the polymerase chain reaction (PCR) has variously been described as a classic "Eureka!" moment, or as an example of cooperative teamwork between disparate researchers. Following is a list of events before, during, and after its development:

Integrated DNA Technologies, Inc. (IDT), headquartered in Coralville, Iowa, is a supplier of custom nucleic acids, serving the areas of academic research, biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacturing of custom DNA and RNA oligonucleotides (oligos) for research applications.

<span class="mw-page-title-main">MAGIChip</span>

MAGIChips, also known as "microarrays of gel-immobilized compounds on a chip" or "three-dimensional DNA microarrays", are devices for molecular hybridization produced by immobilizing oligonucleotides, DNA, enzymes, antibodies, and other compounds on a photopolymerized micromatrix of polyacrylamide gel pads of 100x100x20 μm or smaller size. This technology is used for analysis of nucleic acid hybridization, specific binding of DNA, and low-molecular weight compounds with proteins, and protein-protein interactions.

Eurogentec is a biotechnology supplier, based in Belgium, that specializes in genomics and proteomics kits, reagents, and certain biologics. It was founded in 1985 as a spin-off from the University of Liège. Eurogentec operates two licensed contract manufacturing organization facilities in Belgium which produce custom biologic and oligonucleotide products mainly for European pharmaceutical companies, but also holds a license from the U.S. FDA to export a commercial protein product to the U.S.. These products are used to diagnose and treat various conditions.

<span class="mw-page-title-main">Black Hole Quencher 1</span> Chemical compound

Black Hole Quencher 1 (BHQ1) is an example of dark quencher, which is used to quench green and yellow dyes, such as 6-carboxyfluorescein (6-FAM), tetrachlorofluorescein (TET), and hexachlorofluorescein (HEX). The role of quenchers is to absorb energy from a fluorophore and to re-emit the energy in the form of either heat or visible light. The absorption range of BHQ1 is from 480 to 580 nm with maximum absorption at 534 nm.

References

  1. https://www.biosearchtech.com/about-us/inside-lgc-biosearch
  2. https://find-and-update.company-information.service.gov.uk/company/07686158/filing-history/MzQwODA1OTE4NmFkaXF6a2N4/document?format=pdf&download=0 See page 8
  3. "Biosearch eyes European growth with two acquisitions", Genetic Engineering & Biotechnology News , vol. 33, no. 6 (paper ed.), p. 8, March 15, 2013
  4. "LGC acquires Biosearch Technologies and extends its expertise in the qPCR market". www.lgcgroup.com. Retrieved 2024-02-16.
  5. "LGC acquires Douglas Scientific to expand its high-throughput PCR platform offering". www.lgcgroup.com. Retrieved 2024-02-16.
  6. Kary B. Mullis' Nobel Lecture, December 8, 1993
  7. Glen Research - Black Hole Quencher Webpage
  8. Sigma Aldrich - Black Hole Quencher Webpage
  9. Genetic Engineering News - RealTimeDesign